文献速递免疫规划妇幼与学校卫生传染病防控与疫情报告

高风险儿童中的百日咳疾病负担与无细胞百日咳疫苗效果

Pertussis burden and acellular pertussis vaccine effectiveness in high risk children.
PubMed 文献 · Vaccine · 2022-01-31

在澳大利亚两个州2001-2012年出生并随访至18个月的130余万名儿童中, Aboriginal儿童、有合并症儿童及早产儿是百日咳住院的高风险亚组;无细胞百日咳疫苗在Aboriginal与非Aboriginal儿童中均有显著保护,但在有合并症儿童中首剂和第二剂后保护不显著,第三剂后对住院百日咳有显著保护。

要点

  • Aboriginal与非Aboriginal儿童接种1、2、3剂后对住院百日咳均有显著保护。
  • 有合并症儿童接种1剂后VE为0%、2剂后为30%,均不显著。
  • 有合并症儿童接种3剂后对住院百日咳VE为70%(95%CI 29-87),对非住院百日咳不显著。

核心结论

  • 对多数Aboriginal与非Aboriginal儿童,提高现有婴儿剂次的及时性和产前覆盖应能进一步改善对任何严重程度百日咳的保护。
  • 对严重百日咳最高风险儿童(孕周<32周出生或有显著合并症),数据提示需要额外措施如增加含百日咳疫苗剂次和/或免疫原性更好的疫苗来提供保护。

研究设计与样本

  • 基于澳大利亚两个州(西澳大利亚州和新南威尔士州)2001-2012年出生记录的人群队列,链接围产期、疾病通知、住院、死亡和接种数据,随访至2013年底。
  • 随访至18月龄的儿童按Aboriginal身份、早产(<32周 vs 32-<37周妊娠)和出院编码识别的合并症分层。
  • 使用调整Cox比例风险模型计算首次住院和非住院百日咳通知的率、率比和疫苗效果。

主要发现

  • 在超过130万名儿童中,63,867名(4.9%)为Aboriginal,47,721名(3.6%)有至少一种合并症,18月龄内发生3,771次首次百日咳通知,其中1,207次(32.0%)有相关百日咳编码住院。
  • Aboriginal与非Aboriginal儿童住院百日咳:第1剂后VE分别为51%与25%,第2剂后分别为69%与74%,第3剂后分别为76%与80%,均有显著保护。
  • 有合并症儿童住院百日咳:第1剂后VE为0%、第2剂后为30%,均不显著;第3剂后VE为70%(95%CI 29-87)显著,非住院百日咳VE为24%(95%CI -49至61)不显著。

临床怎么用

  • 作者认为,对多数Aboriginal与非Aboriginal儿童,改善现有婴儿剂次的及时性和提高产前覆盖应能进一步改善对任何严重程度百日咳的保护。
  • 作者认为,对孕周<32周出生或有显著合并症的严重百日咳最高风险儿童,数据提示需要额外措施如增加含百日咳疫苗剂次和/或免疫原性更好的疫苗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pertussis hospitalisation is more common among infants born prematurely, who have significant comorbidities, or are Indigenous, but acellular pertussis (aP) vaccine effectiveness (VE) estimates in these sub-groups are lacking. We measured aP VE by Indigenous status, and policy-relevant categories of prematurity and comorbidity, in a population-based Australian cohort. METHODS: Perinatal, disease notification, hospitalisation, mortality, and vaccination data were linked to birth records in two Australian states (Western Australia and New South Wales) 2001-2012, with follow-up to the end of 2013. Children followed to 18 months of age were stratified by Aboriginality, prematurity (<32 vs 32-<37 weeks gestation) and comorbidities identified from hospital discharge coding. Rates, rate ratios and VE were calculated for first episode of hospitalised and non-hospitalised pertussis notifications using adjusted Cox proportional hazards models. RESULTS: Among >1,300,000 children, 63,867 (4·9%) were Aboriginal, 47,721 (3·6%) had at least one comorbidity and 3,771 first episodes of notified pertussis occurred <18 months of age; of these, 1,207 (32.0%) had an associated pertussis-coded hospitalisation. For hospitalised pertussis in Aboriginal and non-Aboriginal children, there was significant protection post dose 1 (VE 51% v 25%), 2 (VE 69% v 74%) and 3 (VE 76% v 80%). For children with co-morbidities, VE for hospitalised pertussis was low and non-significant post dose 1 (0%) and 2 (30%). Post dose 3, VE was significant for hospitalised pertussis (70%; 95% CI 29-87) but not for non-hospitalised pertussis (24%; 95% CI -49 to 61). CONCLUSIONS: For most Aboriginal and non-Aboriginal children, improved timeliness of current infant doses and higher antenatal coverage should further improve protection against pertussis of any severity. For children at highest risk of severe pertussis (born <32 weeks gestation or with significant medical comorbidities), our data suggest that additional measures-such as extra doses of pertussis-containing vaccines and/or vaccines with improved immunogenicity-are needed for protection.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Sheridan S, McIntyre P, Liu B, et al. Pertussis burden and acellular pertussis vaccine effectiveness in high risk children. Vaccine. 2022. PMID: 35101268. doi:10.1016/j.vaccine.2021.10.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。